Dual antiplatelet therapy beyond 12 months versus for 12 months after drug-eluting stents for acute myocardial infarction
- Authors
- Sim, D.S.; Jeong, M.H.; Kim, H.S.; Gwon, H.C.; Seung, K.B.; Rha, S.W.; Chae, S.C.; Kim, C.J.; Cha, K.S.; Park, J.S.; Yoon, J.H.; Chae, J.K.; Joo, S.J.; Choi, D.J.; Hur, S.H.; Seong, I.W.; Cho, M.C.; Kim, D.I.; Oh, S.K.; Ahn, T.H.; Hwang, J.Y.
- Issue Date
- Jan-2020
- Publisher
- Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
- Keywords
- Antiplatelet agents; Drug-eluting stents; Myocardial infarction
- Citation
- Journal of Cardiology
- Journal Title
- Journal of Cardiology
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/2059
- DOI
- 10.1016/j.jjcc.2019.06.006
- ISSN
- 0914-5087
- Abstract
- Background: The optimal duration of dual antiplatelet therapy (DAPT) after acute coronary syndrome remains uncertain. This study investigated the benefit of DAPT beyond 12 months after drug-eluting stents (DES) for acute myocardial infarction (MI). Methods: From Korea Acute Myocardial Infarction Registry-National Institute of Health database, 6199 patients treated with DAPT for 12 months after DES (second-generation DES 98%) without ischemic or bleeding events were analyzed. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), a composite of death from any cause, MI, or ischemic stroke during the period from 12 to 24 months. Results: After adjustment using inverse probability of treatment weighting, patients who received DAPT beyond 12 months (n = 4795), compared to patients treated with 12-month DAPT (n = 1404), had a similar incidence of MACCE (1.3% vs. 1.0%, HR: 1.32, 95% CI: 0.71–2.45, p = 0.378). The 2 groups did not differ significantly in the rates of death (0.1% vs. 0.1%), MI (0.8% vs.0.6%), stent thrombosis (0.1% vs. 0.2%), ischemic stroke (0.4% vs. 0.2%), and major bleeding (0.1% vs. 0.1%). The rate of net adverse clinical events was 1.4% with DAPT beyond 12 months and 1.1% with 12-month DAPT (p = 0.466). Conclusions: DAPT beyond 12 months, as compared with 12-month DAPT, in real-world patients with acute MI treated predominantly with second-generation DES did not reduce the risk of MACCE. The rates of major bleeding and net adverse clinical events did not differ significantly between the 2 treatments. © 2019 Japanese College of Cardiology
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/2059)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.